High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation
High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation
复制标题
DOI：
10.3109/10428194.2015.1037764
复制
发表时间：
2015-12-02
影响因子：
2.6
通讯作者：
Sureda, Anna
中科院分区：
文献类型：
--
作者：
Fox, Christopher P.;Boumendil, Ariane;Sureda, Anna
结外NK/T淋巴瘤（ENKTL）是罕见的，在东亚较为常见。高剂量治疗和自体干细胞移植（HDT-ASCT）在ENKTL中的作用尚不清楚。本研究研究了2000-2009年在欧洲接受HDT-ASCT的28例可评估患者。中位年龄为47岁，患者既往接受过中位两种治疗。约57%的患者在HDT-ASCT中没有完全缓解或超过首次完全缓解。1年非复发死亡率（NRM）为11%；2年无进展生存率（PFS）和总生存率（OS）分别为41%和52%。值得注意的是，III/IV期疾病患者的2年PFS和OS分别为33%和40%，hdt - asct后1年以上无复发。这是西半球报道的最大规模的ENKTL患者HDT-ASCT分析。生存率与东亚队列相当，晚期疾病患者的预后令人鼓舞。
Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease.